BeiGene’s Brukinsa Set To Take On Imbruvica With CLL Approval

 
• By Joseph Haas

The BTK inhibitor demonstrated superiority to AbbVie/J&J’s Imbruvica for overall response in relapsed/refractory CLL, in addition to hitting a progression-free survival endpoint versus chemotherapy in the first-line.

BeiGene's Brukinsa adds US indication for chronic lymphocytic leukemia • Source: Shutterstock

More from New Products

More from Scrip